U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07219121) titled 'Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis' on Oct. 09.
Brief Summary: To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
Study Start Date: Oct. 07
Study Type: INTERVENTIONAL
Condition:
Proteinuria
Immunoglobulin A (IgA) Nephropathy
Focal Segmental Glomerulosclerosis
Kidney Transplant
Intervention:
DRUG: Sparsentan
For participants with a kidney transplant with IgAN:
Day 1 through Week 2 visit, patients will take 200 mg once daily (QD) prior to the mornin...